Mereo BioPharma Group plc Revenue 2011-2026 | MREO

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Mereo BioPharma Group plc

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	36.5 M	-	-	-	-	-	-	-	-	-	-

All numbers in GBP currency

Indicator range from annual reports

Maximum	Minimum	Average
36.5 M	36.5 M	36.5 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Alterity Therapeutics Limited ATHE	109 K	$ 4.58	-	$ 11 B	Australia
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	912 K	$ 0.88	-	$ 6.47 M	China
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	958 M	$ 22.67	-	$ 3.76 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Applied Therapeutics APLT	9.99 M	-	-	$ 8.42 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Genmab A/S GMAB	10.1 B	$ 26.79	-	$ 16.8 B	Danmark
Avenue Therapeutics ATXI	1.4 M	-	-52.27 %	$ 4.45 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Aeterna Zentaris AEZS	7.5 M	-	5.93 %	$ 314 M	Canada
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	3.09 M	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	482 M	$ 102.06	-	$ 27.2 B	Germany
BioDelivery Sciences International BDSI	167 M	-	-4.8 %	$ 255 M	USA
Innoviva INVA	411 M	$ 23.69	-	$ 1.6 B	USA
Aquestive Therapeutics AQST	44.5 M	$ 4.09	-	$ 437 M	USA
Arcutis Biotherapeutics ARQT	376 M	$ 23.29	-	$ 2.96 B	USA
Jaguar Health JAGX	11.5 M	$ 0.24	-	$ 560 K	USA
KalVista Pharmaceuticals KALV	49.1 M	$ 19.24	-	$ 1.04 B	Britain
Autolus Therapeutics plc AUTL	75.4 M	$ 1.48	-	$ 394 M	Britain
Kamada Ltd. KMDA	180 M	$ 8.15	-	$ 260 M	Israel
Kazia Therapeutics Limited KZIA	1.07 M	$ 11.85	-	$ 1.57 B	Australia
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
Can-Fite BioPharma Ltd. CANF	853 K	$ 2.91	-	$ 4.79 M	Israel
BeiGene, Ltd. BGNE	5.34 B	-	0.49 %	$ 251 B	Cayman-islands
Evogene Ltd. EVGN	3.85 M	$ 0.79	-0.65 %	$ 27.9 M	Israel